Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92

Eugenio Morelli, Lavinia Biamonte, Cinzia Federico, Nicola Amodio, Maria Teresa Di Martino, Maria Eugenia Gallo Cantafio, Martina Manzoni, Francesca Scionti, Mehmet Kemal Samur, Annamaria Gullà, Maria Angelica Stamato, Maria Rita Pitari, Daniele Caracciolo, Settimio Sesti, Niels M. Frandsen, Marco Rossi, Antonino Neri, Mariateresa Fulciniti, Nikhil C. Munshi, Pierosandro Tagliaferri, Pierfrancesco Tassone

Open source

DOI: 10.1182/blood-2018-03-836601
Published: 2018-09-06
Container: Blood
Publisher: American Society of Hematology
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1182/blood-2018-03-836601,
  title = {Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92},
  author = {Eugenio Morelli and Lavinia Biamonte and Cinzia Federico and Nicola Amodio and Maria Teresa Di Martino and Maria Eugenia Gallo Cantafio and Martina Manzoni and Francesca Scionti and Mehmet Kemal Samur and Annamaria Gullà and Maria Angelica Stamato and Maria Rita Pitari and Daniele Caracciolo and Settimio Sesti and Niels M. Frandsen and Marco Rossi and Antonino Neri and Mariateresa Fulciniti and Nikhil C. Munshi and Pierosandro Tagliaferri and Pierfrancesco Tassone},
  year = {2018},
  journal = {Blood},
  doi = {10.1182/blood-2018-03-836601},
  url = {https://doi.org/10.1182/blood-2018-03-836601}
}

RIS

TY  - JOUR
TI  - Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92
AU  - Eugenio Morelli
AU  - Lavinia Biamonte
AU  - Cinzia Federico
AU  - Nicola Amodio
AU  - Maria Teresa Di Martino
AU  - Maria Eugenia Gallo Cantafio
AU  - Martina Manzoni
AU  - Francesca Scionti
AU  - Mehmet Kemal Samur
AU  - Annamaria Gullà
AU  - Maria Angelica Stamato
AU  - Maria Rita Pitari
AU  - Daniele Caracciolo
AU  - Settimio Sesti
AU  - Niels M. Frandsen
AU  - Marco Rossi
AU  - Antonino Neri
AU  - Mariateresa Fulciniti
AU  - Nikhil C. Munshi
AU  - Pierosandro Tagliaferri
AU  - Pierfrancesco Tassone
PY  - 2018
JO  - Blood
DO  - 10.1182/blood-2018-03-836601
UR  - https://doi.org/10.1182/blood-2018-03-836601
ER  -

APA

Morelli, E., Biamonte, L., Federico, C., Amodio, N., Martino, M. T. D., Cantafio, M. E. G., Manzoni, M., Scionti, F., Samur, M. K., Gullà, A., Stamato, M. A., Pitari, M. R., Caracciolo, D., Sesti, S., Frandsen, N. M., Rossi, M., Neri, A., Fulciniti, M., Munshi, N. C., Tagliaferri, P., & Tassone, P. (2018). Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92. Blood. https://doi.org/10.1182/blood-2018-03-836601

Source records

crossref · retrieved 2026-09-27T00:22:44.713Z